Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001783146 | SCV002021769 | pathogenic | Arrhythmogenic right ventricular dysplasia 11 | 2019-11-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002414342 | SCV002721876 | pathogenic | Cardiovascular phenotype | 2019-04-02 | criteria provided, single submitter | clinical testing | The p.Q620* pathogenic mutation (also known as c.1858C>T), located in coding exon 12 of the DSC2 gene, results from a C to T substitution at nucleotide position 1858. This changes the amino acid from a glutamine to a stop codon within coding exon 12. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV001783146 | SCV003330469 | pathogenic | Arrhythmogenic right ventricular dysplasia 11 | 2022-03-23 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1322771). This variant has not been reported in the literature in individuals affected with DSC2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gln620*) in the DSC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DSC2 are known to be pathogenic (PMID: 23911551). |